Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q408565> ?p ?o }
Showing triples 1 to 45 of
45
with 100 triples per page.
- Q408565 subject Q8248726.
- Q408565 subject Q8758634.
- Q408565 subject Q8788974.
- Q408565 subject Q8872471.
- Q408565 subject Q9052323.
- Q408565 abstract "Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.Rufinamide was approved by the US Food and Drug Administration on November 14, 2008 as adjunctive treatment of seizures associated with Lennox-Gastaut syndromein children 4 years and older and adults. Its official FDA-approved labeling does not mention use in the treatment of partial seizures inasmuch as clinical trials submitted to the FDA were marginal. However, several recent clinical trials suggest that the drug has efficacy for partial seizures It is marketed under the brand name Banzel. It is also marketed in the European Union under the brand name Inovelon.The mechanism of action of rufinamide is unknown. There is some evidence that rufinamide can modulate the gating of voltage-gated sodium channels, a common target for antiepileptic drugs. A recent study indicates subtle effects on the voltage-dependence of gating and the time course of inactivation in some sodium channel isoforms that could reduce neuronal excitability. However, this action cannot explain the unique spectrum of activity of rufinamide.".
- Q408565 atcPrefix "N03".
- Q408565 atcSuffix "AF03".
- Q408565 casNumber "106308-44-5".
- Q408565 fdaUniiCode "WFW942PR79".
- Q408565 iupacName "1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide".
- Q408565 pubchem "129228".
- Q408565 thumbnail Rufinamid.svg?width=300.
- Q408565 wikiPageExternalLink rufinamide_050913.html.
- Q408565 wikiPageExternalLink rufinamide.
- Q408565 wikiPageExternalLink Rufinamide.
- Q408565 wikiPageWikiLink Q1544884.
- Q408565 wikiPageWikiLink Q204711.
- Q408565 wikiPageWikiLink Q3271540.
- Q408565 wikiPageWikiLink Q41571.
- Q408565 wikiPageWikiLink Q424960.
- Q408565 wikiPageWikiLink Q507154.
- Q408565 wikiPageWikiLink Q576618.
- Q408565 wikiPageWikiLink Q8248726.
- Q408565 wikiPageWikiLink Q8758634.
- Q408565 wikiPageWikiLink Q8788974.
- Q408565 wikiPageWikiLink Q8872471.
- Q408565 wikiPageWikiLink Q903341.
- Q408565 wikiPageWikiLink Q903384.
- Q408565 wikiPageWikiLink Q9052323.
- Q408565 atcPrefix "N03".
- Q408565 atcSuffix "AF03".
- Q408565 casNumber "106308".
- Q408565 iupacName "1".
- Q408565 pubchem "129228".
- Q408565 unii "WFW942PR79".
- Q408565 type ChemicalSubstance.
- Q408565 type Drug.
- Q408565 type ChemicalObject.
- Q408565 type Thing.
- Q408565 type Q8386.
- Q408565 comment "Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.Rufinamide was approved by the US Food and Drug Administration on November 14, 2008 as adjunctive treatment of seizures associated with Lennox-Gastaut syndromein children 4 years and older and adults.".
- Q408565 label "Rufinamide".
- Q408565 differentFrom Q21098885.
- Q408565 depiction Rufinamid.svg.